Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Nutriband Inc. Warrant

Healthcare US NTRBW

0.9USD
0.05(5.88%)

Last update at 2026-06-03T15:58:00Z

Day Range

0.900.90
LowHigh

52 Week Range

0.192.11
LowHigh

Fundamentals

  • Previous Close 0.85
  • Market Cap0.00000M
  • Volume103
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.58420M
  • Revenue TTM2.09M
  • Revenue Per Share TTM0.26
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.51

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Income before tax -4.48347M -6.17613M -2.93283M -2.72163M -3.33124M
Minority interest - - - - -
Net income -4.81080M -8.42235M -3.21351M -2.79504M -3.33124M
Selling general administrative 3.92M 4.02M 4.02M 1.79M 3.29M
Selling and marketing expenses - - - - -
Gross profit 0.75M 0.50M 0.36M -0.17846M -0.04302M
Reconciled depreciation 0.37M 0.32M 0.17M 0.09M 0.04M
Ebit -4.14786M -3.92990M -2.59594M -1.96944M -3.33124M
Ebitda -3.77890M -3.61163M -2.49536M -1.87803M -3.29423M
Depreciation and amortization 0.37M 0.32M 0.10M 0.09M 0.04M
Non operating income net other - - - - -
Operating income -4.14786M -3.92990M -2.59594M -1.96944M -3.33124M
Other operating expenses 6.23M 5.35M 3.54M 2.34M 3.58M
Interest expense 0.00829M 0.12M 0.28M 0.07M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income -0.00829M -0.11842M -0.34982M -0.07341M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.33M 2.25M 0.28M 0.07M -
Total revenue 2.08M 1.42M 0.94M 0.37M 0.25M
Total operating expenses 4.90M 4.43M 2.96M 1.79M 3.29M
Cost of revenue 1.33M 0.92M 0.58M 0.55M 0.29M
Total other income expense net -0.33561M -2.24623M -0.33688M -0.75219M -
Discontinued operations - - - - -
Net income from continuing ops -4.48347M -6.17613M -2.93283M -2.72163M -3.33124M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Type yearly yearly yearly yearly yearly
Date 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Total assets 7.52M 9.46M 12.74M 9.93M 2.20M
Intangible assets 0.67M 0.78M 0.93M 1.01M 0.31M
Earning assets - - - - -
Other current assets 0.21M 0.37M 0.37M 0.37M 0.02M
Total liab 1.08M 0.88M 0.88M 2.82M 2.02M
Total stockholder equity 6.44M 8.57M 11.86M 7.11M 0.18M
Deferred long term liab - - - - -
Other current liab 0.68M 0.53M 0.64M 0.94M 0.93M
Common stock 0.00886M 0.00783M 0.00784M 0.00626M 0.00544M
Capital stock 0.00886M 0.00783M 0.00784M 0.00626M 0.00544M
Retained earnings -27.98002M -22.49470M -18.01123M -11.83511M -8.90228M
Other liab - - - - -
Good will 5.02M 5.02M 5.35M 7.53M 1.72M
Other assets - - - - -
Cash 0.49M 1.99M 4.89M 0.15M 0.01M
Cash and equivalents - - - - -
Total current liabilities 1.00M 0.75M 0.78M 2.57M 2.02M
Current deferred revenue 0.16M 0.16M 0.11M 0.09M -
Net debt -0.25166M -1.79964M -4.75730M 1.64M 0.31M
Short term debt 0.16M 0.05M 0.03M 1.54M 0.32M
Short long term debt 0.13M 0.02M 0.01M 1.52M 0.31M
Short long term debt total 0.24M 0.19M 0.13M 1.79M 0.32M
Other stockholder equity 34.41M 31.06M 29.86M 18.94M 9.07M
Property plant equipment - - - - -
Total current assets 1.02M 2.69M 5.47M 0.31M 0.04M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.15M 0.11M 0.07M 0.11M 0.01M
Long term debt 0.08M 0.10M 0.10M 0.15M -
Inventory 0.17M 0.23M 0.13M 0.05M -
Accounts payable 0.68M - 0.64M - 0.77M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00030M -0.00030M -0.00030M -0.00030M -0.00030M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 6.50M 6.76M 7.27M 9.61M 2.15M
Capital lease obligations 0.03M 0.07M 0.02M 0.12M 0.01M
Long term debt total - - - - -
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Investments -0.07930M -0.08160M 0.07M 0.00000M -0.40416M
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 0.16M 7.63M 0.37M 0.43M 1.98M
Change to operating activities - - - - -
Net income -4.48347M -6.17613M -2.93283M -2.72163M -3.33124M
Change in cash -2.90643M 4.74M 0.14M -0.46447M 0.47M
Begin period cash flow 4.89M 0.15M 0.01M 0.47M 0.09M
End period cash flow 1.99M 4.89M 0.15M 0.01M 0.47M
Total cash from operating activities -2.98720M -2.80922M -0.29706M -0.89447M -1.10547M
Issuance of capital stock 0.00000M 6.42M 0.52M 0.00000M 1.50M
Depreciation 0.37M 0.32M 0.17M 0.09M 0.04M
Other cashflows from investing activities - - - - -
Dividends paid - -0.19659M - - -
Change to inventory -0.09769M -0.07880M -0.01023M 0.00000M 0.00413M
Change to account receivables -0.04167M 0.04M -0.09475M 0.00026M -0.01282M
Sale purchase of stock -0.11901M -0.10447M -0.10447M - -
Other cashflows from financing activities 0.30M 3.14M 0.21M 0.43M 0.53M
Change to netincome - - - - -
Capital expenditures 0.08M 0.08M 0.08M 0.00000M 0.00416M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.21932M -0.54138M 0.11M 0.71M 0.40M
Stock based compensation 0.73M 1.36M 2.00M 0.25M 1.76M
Other non cash items 0.61M 2.23M 0.36M 0.09M 0.02M
Free cash flow -3.06650M -2.89082M -0.29706M -0.89447M -1.10963M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
NTRBW
Nutriband Inc. Warrant		 0.05 5.88% 0.90 - - - -
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Nutriband Inc. Warrant

121 South Orange Avenue, Orlando, FL, United States, 32801

Key Executives

Name Title Year Born
Mr. Serguei Melnik Founder, President, Company Secretary & Executive Chairman of the Board 1974
Mr. Gareth Sheridan Founder, CEO & Director 1990
Mr. Gerald Goodman CFO & Chief Accounting Officer 1948
Dr. Alan Smith Ph.D. COO & President of 4P Therapeutics 1966
Mr. Patrick Ryan Chief Technical Officer 1986
Dr. Jeffrey Patrick Pharm.D. Chief Scientific Officer 1970
Mr. Tyler Overk President of Active Intelligence 1984

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.